Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Chemomab Therapeutics Ltd. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +1 vs. Q3 2024
- Shares held
- 4.16M
- −389.0K (−8.6%) vs. Q3 2024
- Total value
- $7.53M
- +$387.9K (+5.4%) vs. Q3 2024
- New holders
- 5
- 1 more added
- Sold out
- 4
- 6 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $615.3K |
| Q1 2026 | 15 | $551.9K |
| Q4 2025 | 14 | $606.1K |
| Q3 2025 | 10 | $1.03M |
| Q2 2025 | 14 | $4.91M |
| Q1 2025 | 17 | $4.07M |
| Q4 2024 | 16 | $7.53M |
| Q3 2024 | 15 | $7.14M |
| Q2 2024 | 15 | $2.44M |
| Q1 2024 | 14 | $2.07M |
| Q4 2023 | 16 | $1.43M |
| Q3 2023 | 11 | $2.26M |
| Q2 2023 | 11 | $3.33M |
| Q1 2023 | 13 | $4.56M |
| Q4 2022 | 14 | $10.6M |
| Q3 2022 | 15 | $8.09M |
| Q2 2022 | 13 | $12.2M |
| Q1 2022 | 15 | $15.9M |
| Q4 2021 | 14 | $22.7M |
| Q3 2021 | 15 | $35.9M |
| Q2 2021 | 12 | $58.7M |
| Q1 2021 | 10 | $82.6M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Chemomab Therapeutics Ltd.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 1,741,273 | $3.15M | 0.07% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 1,214,575 | $2.20M | 0.41% | 00.0% | Unchanged |
| Yelin Lapidot Holdings Management Ltd. | 744,127 | $1.35M | 0.23% | −65,590−8.1% | Reduced |
| Ikarian Capital, LLC | 213,052 | $385.6K | 0.11% | −340−0.2% | Reduced |
| Morgan Stanley | 104,400 | $189.0K | 0.00% | −297,872−74.0% | Reduced |
| Kestra Private Wealth Services, LLC | 31,241 | $56.5K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 26,189 | $47.4K | 0.00% | −340−1.3% | Reduced |
| XTX Topco Ltd | 24,929 | $45.1K | 0.00% | +9,706+63.8% | Added |
| Rhumbline Advisers | 23,808 | $43.1K | 0.00% | −3,765−13.7% | Reduced |
| Virtu Financial LLC | 14,445 | $26.0K | 0.00% | +14,445 | New |
| Wetzel Investment Advisors, Inc. | 10,000 | $18.1K | 0.01% | +10,000 | New |
| BNP Paribas Arbitrage, SA | 6,500 | $11.8K | 0.00% | +6,500 | New |
| GAMMA Investing LLC | 5,099 | $9.23K | 0.00% | +5,099 | New |
| Moser Wealth Advisors, LLC | 500 | $905 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 485 | $878 | 0.00% | −1,803−78.8% | Reduced |
| SBI Securities Co., Ltd. | 100 | $181 | 0.00% | +100 | New |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −39,939−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −13,579−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −10,565−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1,101−100.0% | Sold out |